浸潤性乳管がん治療市場規模、シェア、動向分析レポート：治療法別、タイプ別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

浸潤性乳管がん治療市場の成長と動向

浸潤性乳管がん治療の世界市場規模は、2030年には152億1,000万米ドルに達すると予測され、2025～2030年にかけてCAGR 8.50％で成長すると予測されます。

この市場には、この一般的な乳がんと診断された患者の管理とケアに貢献する幅広い要素が含まれています。

乳がんとその早期発見に対する意識の高まりにより、定期的な検診を受ける女性が増えました。米国がん協会は、定期的なマンモグラフィ検査によって、治療可能な早期段階で乳がんを発見できると報告しています。このような意識の高まりは、早期診断に貢献し、より多くの症例が確認されるにつれて、効果的なIDC治療への需要が高まります。

政府の承認プロセスには、米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関による厳格な評価が含まれます。これらの機関は臨床検査データを評価し、承認前に新しい治療法の安全性と有効性を確認します。例えば、2024年3月、AstraZenecaのトゥルーカップ（Capivasertib）は、ホルモン受容体陽性、HER2陰性、PIK3CA、AKT1、PTENに変異があり、内分泌療法後に病勢進行した切除不能または再発乳がんの成人患者を対象に、ファスロデックス（フルベストラント）と併用する治療として日本で承認を取得しました。

浸潤性乳管がん治療市場レポートハイライト

• 治療法別では、標的治療が2024年に65.29%の最大売上シェアで市場を独占しました。製薬企業が新規の標的薬や併用療法の開発に投資を続けていることから、標的療法は浸潤性乳管がん治療において主要な地位を維持すると予想されます。
• タイプ別では、ホルモン受容体が2024年に65.33%の最大売上シェアで市場を独占します。個別化医療に対する意識の高まりと重視が、ホルモン受容体治療市場を強化しています。医療プロバイダーは、個々の患者に合わせた治療を行うためにバイオマーカー検査を利用するようになっており、ホルモン受容体の状態を特定することは治療計画において極めて重要になっています。
• 流通チャネル別では、病院薬局が2024年に45.53％の最大売上高シェアで市場を独占しました。この優位性は、患者が包括的な治療を受ける病院環境で投与される化学療法や標的療法への依存度が高まっていることなど、いくつかの要因によってもたらされます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 浸潤性乳管がん治療市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 浸潤性乳管がん治療市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 浸潤性乳管がん治療市場：治療法別、推定・動向分析

• 世界の浸潤性乳管がん治療市場：治療ダッシュボード
• 世界の浸潤性乳管がん治療市場：治療変動分析
• 世界の浸潤性乳管がん治療市場（治療、収益別）
• 標的療法
  • アベマシクリブ
  • アドトラスツズマブエムタンシン
  • エベロリムス
  • トラスツズマブ
  • リボシクリブ
  • パルボシクリブ
  • ペルツズマブ
  • オラパリブ
  • その他
• ホルモン療法
  • 選択的エストロゲン受容体モジュレーター（SERM）
  • アロマターゼ阻害剤
  • エストロゲン受容体ダウンレギュレーター（ERD）
• 化学療法
• 免疫療法

第5章 浸潤性乳管がん治療市場：タイプ別、推定・動向分析

• 世界の浸潤性乳管がん治療市場：タイプダッシュボード
• 世界の浸潤性乳管がん治療市場：タイプ変動分析
• タイプ別、収益
• ホルモン受容体
• HER2+

第6章 浸潤性乳管がん治療市場：流通チャネル別、推定・動向分析

• 世界の浸潤性乳管がん治療市場：流通チャネルダッシュボード
• 世界の浸潤性乳管がん治療市場：流通チャネル変動分析
• 流通チャネル別、収益
• 病院薬局
• 小売薬局
• その他

第7章 浸潤性乳管がん治療市場：治療法、タイプ、流通チャネルによる地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店とチャネルパートナー一覧
  • 主要企業の市場シェア分析、2024年
  • Novartis AG
  • Pfizer
  • Merck KGaA
  • Janssen Global Services, LLC
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Macrogenics, Inc.
  • Celldex Therapeutics

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 4 North America Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 5 North America Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 U.S. Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 7 U.S. Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 8 U.S. Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 9 Canada Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 10 Canada Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 11 Canada Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 12 Mexico Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 13 Mexico Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 14 Mexico Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 15 Europe Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 17 Europe Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 18 Europe Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 19 Germany Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 20 Germany Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 21 Germany Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 22 UK Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 23 UK Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 24 UK Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25 France Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 26 France Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 27 France Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 Italy Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 29 Italy Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 30 Italy Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 31 Spain Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 32 Spain Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 33 Spain Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34 Denmark Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 35 Denmark Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 36 Denmark Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 37 Sweden Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 38 Sweden Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 39 Sweden Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 40 Norway Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 41 Norway Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 42 Norway Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 47 China Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 48 China Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 49 China Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50 Japan Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 51 Japan Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 52 Japan Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 53 India Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 54 India Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 55 India Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 56 South Korea Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 57 South Korea Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 58 South Korea Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 59 Australia Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 60 Australia Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 61 Australia Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62 Thailand Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 63 Thailand Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 64 Thailand Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 65 Latin America Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
• Table 66 Latin America Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 67 Latin America Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 68 Latin America Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 69 Brazil Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 70 Brazil Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 71 Brazil Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 72 Argentina Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 73 Argentina Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 74 Argentina Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75 MEA Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
• Table 76 MEA Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 77 MEA Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 78 MEA Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79 South Africa Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 80 South Africa Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 81 South Africa Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 85 UAE Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 86 UAE Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 87 UAE Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 88 Kuwait Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 89 Kuwait Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
• Table 90 Kuwait Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Market research approaches
• Fig. 4 QFD modeling for market share assessment
• Fig. 5 Market formulation & validation
• Fig. 6 Invasive ductal carcinoma treatment market: market outlook
• Fig. 7 Invasive ductal carcinoma treatment competitive insights
• Fig. 8 Parent market outlook
• Fig. 9 Related/ancillary market outlook
• Fig. 10 Invasive ductal carcinoma treatment market driver impact
• Fig. 11 Invasive ductal carcinoma treatment market restraint impact
• Fig. 12 Invasive ductal carcinoma treatment market: therapy movement analysis
• Fig. 13 Invasive ductal carcinoma treatment market: therapy outlook and key takeaways
• Fig. 14 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 15 Abemaciclib market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 16 Ado-trastuzumab emtansine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 Everolimus market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Trastuzumab market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Ribociclib market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Palbociclib market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Pertuzumab market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Olaparib market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Hormonal therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Selective estrogen receptor modulators (SERMs) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Aromatase inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Estrogen receptor down regulators (ERDs) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Invasive ductal carcinoma treatment market: type movement analysis
• Fig. 31 Invasive ductal carcinoma treatment market: type outlook and key takeaways
• Fig. 32 Hormone receptor market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 HER2+ market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Invasive ductal carcinoma treatment market: distribution channel movement analysis
• Fig. 35 Invasive ductal carcinoma treatment market: distribution channel outlook and key takeaways
• Fig. 36 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Global Invasive ductal carcinoma treatment market: Regional movement analysis
• Fig. 40 Global Invasive ductal carcinoma treatment market: Regional outlook and key takeaways
• Fig. 41 Global Invasive ductal carcinoma treatment market share and leading players
• Fig. 42 North America, by country
• Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 U.S. key country dynamics
• Fig. 45 Canada key country dynamics
• Fig. 46 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Mexico key country dynamics
• Fig. 48 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 UK key country dynamics
• Fig. 51 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Germany key country dynamics
• Fig. 53 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 France key country dynamics
• Fig. 55 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Italy key country dynamics
• Fig. 57 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Spain key country dynamics
• Fig. 59 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Denmark key country dynamics
• Fig. 61 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Sweden key country dynamics
• Fig. 63 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Norway key country dynamics
• Fig. 65 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 China key country dynamics
• Fig. 68 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Japan key country dynamics
• Fig. 70 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 India key country dynamics
• Fig. 72 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Thailand key country dynamics
• Fig. 74 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 South Korea key country dynamics
• Fig. 76 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Australia key country dynamics
• Fig. 78 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Brazil key country dynamics
• Fig. 81 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Argentina key country dynamics
• Fig. 83 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 South Africa key country dynamics
• Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Saudi Arabia key country dynamics
• Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 UAE key country dynamics
• Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Kuwait key country dynamics
• Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Market share of key market players- Invasive ductal carcinoma treatment market

Invasive Ductal Carcinoma Treatment Market Growth & Trends:

The global invasive ductal carcinoma treatment market size is expected to reach USD 15.21 billion in 2030 and is projected to grow at a CAGR of 8.50% from 2025 to 2030. The market encompasses a wide range of elements that contribute to the management and care of patients diagnosed with this common form of breast cancer.

Increased awareness about breast cancer and its early detection led to more women undergoing regular screenings. The American Cancer Society reports that regular mammograms can detect breast cancer at an earlier stage when it is more treatable. This heightened awareness contributes to earlier diagnosis and increases the demand for effective IDC treatments as more cases are identified.

The government approval process involves rigorous evaluation by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These agencies assess clinical trial data to ensure that new therapies are safe and effective before approval. For instance, in March 2024, AstraZeneca's Truqap (capivasertib) received approval in Japan for use alongside Faslodex (fulvestrant) to treat adult patients with unresectable or recurrent breast cancer that is hormone receptor-positive, HER2-negative, and has alterations in PIK3CA, AKT1, or PTEN after they experienced disease progression following endocrine therapy.

Invasive Ductal Carcinoma Treatment Market Report Highlights:

• Based on therapy, targeted therapy dominated the market with the largest revenue share of 65.29% in 2024. As pharmaceutical companies continue to invest in developing novel targeted agents and combination therapies, targeted therapy is expected to maintain its leading position in the IDC treatment landscape.
• Based on type, hormone receptors dominated the market with the largest revenue share of 65.33% in 2024. The growing awareness and emphasis on personalized medicine are enhancing the market for hormone receptor therapies. As healthcare providers increasingly utilize biomarker testing to tailor treatments to individual patients, identifying hormone receptor status has become crucial in treatment planning.
• Based on distribution channel, hospital pharmacies dominated the market with the largest revenue share of 45.53% in 2024. This dominance is driven by several factors, including the increasing reliance on chemotherapy and targeted therapies administered in hospital settings, where patients receive comprehensive care.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy
  • 1.2.2. Type
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Therapy Outlook
  • 2.2.2. Type Outlook
  • 2.2.3. Distribution Channel Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Invasive Ductal Carcinoma Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increased Incidence & Prevalence Rate Of Cancer Worldwide
    • 3.2.1.2. High Investment In R&D
    • 3.2.1.3. Technological Advancement In Cancer Biology & Pharmacology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent Regulatory Guidelines
    • 3.2.2.2. Expiry Of Patented Drugs
    • 3.2.2.3. Complications Associated With Chemotherapy
• 3.3. Invasive Ductal Carcinoma Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Invasive Ductal Carcinoma Treatment Market: Therapy Estimates & Trend Analysis

• 4.1. Global Invasive Ductal Carcinoma Treatment Market: Therapy Dashboard
• 4.2. Global Invasive Ductal Carcinoma Treatment Market: Therapy Movement Analysis
• 4.3. Global Invasive Ductal Carcinoma Treatment Market by Treatments, Revenue
• 4.4. Targeted Therapy
  • 4.4.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Abemaciclib
    • 4.4.2.1. Abemaciclib market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Ado-Trastuzumab Emtansine
    • 4.4.3.1. Ado-Trastuzumab Emtansine market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Everolimus
    • 4.4.4.1. Everolimus market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Trastuzumab
    • 4.4.5.1. Trastuzumab market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Ribociclib
    • 4.4.6.1. Ribociclib market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.7. Palbociclib
    • 4.4.7.1. Palbociclib market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.8. Pertuzumab
    • 4.4.8.1. Pertuzumab market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.9. Olaparib
    • 4.4.9.1. Olaparib market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.10. Others
    • 4.4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Hormonal Therapy
  • 4.5.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Selective Estrogen Receptor Modulators (SERMs)
    • 4.5.2.1. Selective estrogen receptor modulators (SERMs) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Aromatase Inhibitors
    • 4.5.3.1. Aromatase inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Estrogen Receptor Down regulators (ERDs)
    • 4.5.4.1. Estrogen receptor down regulators (ERDs) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Chemotherapy
  • 4.6.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Immunotherapy
  • 4.7.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Invasive Ductal Carcinoma Treatment Market: Type Estimates & Trend Analysis

• 5.1. Global Invasive Ductal Carcinoma Treatment Market: Type Dashboard
• 5.2. Global Invasive Ductal Carcinoma Treatment Market: Type Movement Analysis
• 5.3. Global Invasive Ductal Carcinoma Treatment Market Estimates and Forecasts, By Type, Revenue (USD Million)
• 5.4. Hormone Receptor
  • 5.4.1. Hormone receptor market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. HER2+
  • 5.5.1. HER2+ market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Invasive Ductal Carcinoma Treatment Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Invasive Ductal Carcinoma Treatment Market: Distribution Channel Dashboard
• 6.2. Global Invasive Ductal Carcinoma Treatment Market: Distribution Channel Movement Analysis
• 6.3. Global Invasive Ductal Carcinoma Treatment Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Invasive Ductal Carcinoma Treatment Market: Regional Estimates & Trend Analysis by Therapy, Type, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Vendor Landscape
  • 8.2.1. List of key distributors and channel partners
  • 8.2.2. Key company market share analysis, 2024
  • 8.2.3. Novartis AG
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Pfizer
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Merck KGaA
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Janssen Global Services, LLC
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. F. Hoffmann-La Roche Ltd.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. AstraZeneca
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. AbbVie Inc.
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Bristol-Myers Squibb Company
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Macrogenics, Inc.
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Product benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. Celldex Therapeutics
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Product benchmarking
    • 8.2.12.4. Strategic initiatives